시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 항간질약 시장 보고서(2025년)
Antiepileptic Drugs Global Market Report 2025
상품코드 : 1760459
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

항간질약 시장 규모는 향후 수 년간 강력한 성장이 예상됩니다. 예측 기간 동안 예상되는 성장은 약물 내성 뇌전증 환자의 증가, 뇌전증 치료를 위한 개인 맞춤형 의학의 발전, 생물학적 제제 및 유전자 치료제의 채택 증가, 뇌전증 연구 및 개발에 대한 투자 증가에 의해 주도됩니다. 이 기간에 예상되는 주요 동향에는 맞춤형 치료 접근법의 진전, 약제 내성 간질에 대한 병용 요법의 진전, 특정 유전자 변이를 표적으로 한 새로운 치료법, 보다 안전하고 효과적인 항간질제(AED)의 개발에 중점화, 간질 발작 제어를 위한 칸나비디올 기반 치료법의 확대된 사용을 포함합니다.

간질의 유병률 증가는 향후 몇 년간의 항간질약 시장의 성장을 견인할 것으로 예측됩니다. 항필레틱 약물(AED)은 신경전달물질과 이온채널을 조절하여 뇌의 활동을 안정화시키고 신경세포의 과도한 발화를 막음으로써 작용합니다. 2022년 2월 영국의 뇌전증 환자 지원 단체인 Epilepsy Action은 영국에서 약 63만 명(약 100명 중 1명)이 뇌전증을 앓고 있으며, 매일 80건의 새로운 사례가 진단된다고 보고했습니다.

항간질약 시장의 주요 기업은 급성 발작 및 응급 상황에 대한 보다 효과적인 치료 옵션을 제공하기 위해 정맥내 투여 항간질제와 같은 선진 제제의 개발에 주력하고 있습니다. 정맥내 투여 제형은 주사 또는 점적에 의해 혈류에 직접 투여되는 즉각적인 약물이며, 특히 비상시 또는 경구 약물이 적합하지 않거나 효과적이지 않은 경우 신속한 발작 제어를 설명합니다. 예를 들어 2024년 1월 일본 제약회사인 Eisai는 일본에서 Fycompa 제조 판매 승인을 받았습니다. Fycompa는 퍼스트 인 클래스의 고선택적 비경쟁 AMPA 수용체 길항제이며, AMPA 수용체의 글루탐산 활성을 표적으로 함으로써 간질 발작으로 이어지는 신경세포의 흥분 항진을 억제합니다. 점적정주제제는 수술중 등 일시적으로 경구약을 복용할 수 없는 간질환자의 대체약으로서 개발되어 경구투여의 중단에 수반되는 간질발작의 위험을 경감합니다. Fycompa는 75개국 이상에서 승인되었으며, 일본에서는 4세 이상의 부분 간질과 원발성 전반성 강직간대 발작의 병용 요법으로 사용되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

SHW
영문 목차

영문목차

Antiepileptic drugs (AEDs) are medications used to control or prevent seizures in people with epilepsy and other neurological disorders. They work by altering neurotransmitter levels or ion channel function in the brain. By stabilizing electrical activity in the brain, AEDs help decrease both the frequency and severity of seizures.

The main categories of antiepileptic drugs include first-generation, second-generation, and third-generation AEDs. First-generation AEDs were the earliest seizure treatments and act by stabilizing brain activity, though they often come with more side effects and complex pharmacokinetics. These drugs come in various forms, including dry and liquid formulations, and can be administered through multiple routes such as oral and intravenous. They are distributed through a range of channels, including hospital pharmacies, retail pharmacies, online pharmacies, and drug stores.

The antiepileptic drugs market research report is one of a series of new reports from The Business Research Company that provides antiepileptic drugs market statistics, including the antiepileptic drugs industry global market size, regional shares, competitors with the antiepileptic drugs market share, detailed antiepileptic drugs market segments, market trends, opportunities, and any further data you may need to thrive in the antiepileptic drugs industry. This antiepileptic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antiepileptic drugs market size has grown strongly in recent years. It will grow from $17.01 billion in 2024 to $18.00 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be linked to the increasing prevalence of epilepsy, heightened awareness of neurological disorders, progress in drug development, government support and funding for epilepsy research, and the expansion of healthcare infrastructure in emerging markets.

The antiepileptic drugs market size is expected to see strong growth in the next few years. It will grow to $22.27 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The anticipated growth in the forecast period is driven by a rising number of patients with drug-resistant epilepsy, advancements in personalized medicine for epilepsy treatment, increased adoption of biologics and gene therapies, growing investments in epilepsy research and development, and improvements in diagnostics that enhance the identification of epilepsy cases. Key trends expected during this period include the advancement of personalized treatment approaches, progress in combination therapies for drug-resistant epilepsy, emerging therapies targeting specific genetic mutations, a stronger focus on developing safer and more effective antiepileptic drugs (AEDs), and expanded use of cannabidiol-based therapies for seizure control.

The rising prevalence of epilepsy is expected to drive the growth of the antiepileptic drugs market in the coming years. Epilepsy is a neurological disorder marked by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. An increase in head injuries from accidents contributes to a higher risk of developing epilepsy due to brain trauma and neural damage. Antiepileptic drugs (AEDs) work by stabilizing brain activity through modulation of neurotransmitters and ion channels to prevent excessive neuron firing. These drugs reduce both the frequency and severity of seizures, thereby improving the quality of life for people with epilepsy. For example, in February 2022, Epilepsy Action, a UK-based charity that supports individuals with epilepsy, reported that approximately 630,000 people in the UK live with epilepsy-about one in every 100 people-with 80 new cases diagnosed daily. Thus, the growing prevalence of epilepsy is contributing to the expansion of the antiepileptic drug market.

Leading companies in the antiepileptic drugs market are focusing on developing advanced formulations, such as intravenous (IV) antiepileptic drugs, to provide more effective treatment options for acute seizures and emergency situations. IV antiepileptic drugs are fast-acting medications administered directly into the bloodstream via injection or infusion, offering rapid seizure control, especially in emergencies or when oral medications are not suitable or effective. For instance, in January 2024, Eisai Co., Ltd., a Japan-based pharmaceutical firm, received manufacturing and marketing approval for Fycompa in Japan. Fycompa is a first-in-class, highly selective, non-competitive AMPA receptor antagonist that decreases neuronal hyper-excitation linked to seizures by targeting glutamate activity at AMPA receptors. The intravenous formulation was developed as an alternative for epilepsy patients who temporarily cannot take oral medication, such as during surgery, to reduce seizure risks associated with interrupted oral dosing. Fycompa is approved in over 75 countries and is used as an adjunctive treatment for partial-onset seizures and primary generalized tonic-clonic seizures in patients aged 4 years and older in Japan.

In August 2024, AbbVie, a U.S.-based biopharmaceutical company, acquired Cerevel Therapeutics for around $8.7 billion. This acquisition is intended to strengthen AbbVie's neuroscience pipeline and enhance its capacity to develop treatments for neurological and psychiatric disorders. Cerevel Therapeutics is a U.S.-based biotechnology company specializing in the manufacture of antiepileptic drugs.

Major players in the antiepileptic drugs market are Pfizer Inc., Sanofi S.A., Novartis AG, Teva Pharmaceutical Industries Ltd., UCB S.A., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Jazz Pharmaceuticals plc, Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Amneal Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Ltd., Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Supernus Pharmaceuticals Inc., SK Biopharmaceuticals Co. Ltd., Immedica Pharma AB, Neurelis Inc.

North America was the largest region in the antiepileptic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in antiepileptic drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the antiepileptic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antiepileptic drugs market consists of sales of sodium channel blockers, calcium channel blockers, glutamate inhibitors, and gamma-aminobutyric acid (GABA) enhancers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antiepileptic Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antiepileptic drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for antiepileptic drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antiepileptic drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Antiepileptic Drugs Market Characteristics

3. Antiepileptic Drugs Market Trends And Strategies

4. Antiepileptic Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Antiepileptic Drugs Growth Analysis And Strategic Analysis Framework

6. Antiepileptic Drugs Market Segmentation

7. Antiepileptic Drugs Market Regional And Country Analysis

8. Asia-Pacific Antiepileptic Drugs Market

9. China Antiepileptic Drugs Market

10. India Antiepileptic Drugs Market

11. Japan Antiepileptic Drugs Market

12. Australia Antiepileptic Drugs Market

13. Indonesia Antiepileptic Drugs Market

14. South Korea Antiepileptic Drugs Market

15. Western Europe Antiepileptic Drugs Market

16. UK Antiepileptic Drugs Market

17. Germany Antiepileptic Drugs Market

18. France Antiepileptic Drugs Market

19. Italy Antiepileptic Drugs Market

20. Spain Antiepileptic Drugs Market

21. Eastern Europe Antiepileptic Drugs Market

22. Russia Antiepileptic Drugs Market

23. North America Antiepileptic Drugs Market

24. USA Antiepileptic Drugs Market

25. Canada Antiepileptic Drugs Market

26. South America Antiepileptic Drugs Market

27. Brazil Antiepileptic Drugs Market

28. Middle East Antiepileptic Drugs Market

29. Africa Antiepileptic Drugs Market

30. Antiepileptic Drugs Market Competitive Landscape And Company Profiles

31. Antiepileptic Drugs Market Other Major And Innovative Companies

32. Global Antiepileptic Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antiepileptic Drugs Market

34. Recent Developments In The Antiepileptic Drugs Market

35. Antiepileptic Drugs Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기